These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14768954)

  • 1. Magnitude of alloresponses to MHC class I/II expressing human cardiac myocytes is limited by their intrinsic ability to process and present antigenic peptides.
    Sundstrom JB; Jollow KC; Braud V; Villinger F; McMichael AJ; Lawrencec EC; Ades EW; Ansari AA
    Clin Dev Immunol; 2003; 10(2-4):213-26. PubMed ID: 14768954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells.
    Jaraquemada D; Marti M; Long EO
    J Exp Med; 1990 Sep; 172(3):947-54. PubMed ID: 2388037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.
    Seliger B; Dunn T; Schwenzer A; Casper J; Huber C; Schmoll HJ
    Scand J Immunol; 1997 Dec; 46(6):625-32. PubMed ID: 9420627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and molecular mechanisms of human cardiac myocyte injury after transplantation.
    Ansari AA; Sundstrom JB; Kanter K; Mayne A; Villinger F; Gravanis MB; Herskowitz A
    J Heart Lung Transplant; 1995; 14(1 Pt 1):102-12. PubMed ID: 7727458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
    Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
    J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
    Frisan T; Zhang QJ; Levitskaya J; Coram M; Kurilla MG; Masucci MG
    Int J Cancer; 1996 Oct; 68(2):251-8. PubMed ID: 8900437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
    Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
    Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients.
    Pachot A; Monneret G; Brion A; Venet F; Bohé J; Bienvenu J; Mougin B; Lepape A
    Crit Care Med; 2005 Jan; 33(1):31-8; discussion 236-7. PubMed ID: 15644645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis.
    Mulder DJ; Pooni A; Mak N; Hurlbut DJ; Basta S; Justinich CJ
    Am J Pathol; 2011 Feb; 178(2):744-53. PubMed ID: 21281807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinformatics identification of antigenic peptide: predicting the specificity of major MHC class I and II pathway players.
    Lund O; Karosiene E; Lundegaard C; Larsen MV; Nielsen M
    Methods Mol Biol; 2013; 960():247-260. PubMed ID: 23329492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosolic targeting of hen egg lysozyme gives rise to a short-lived protein presented by class I but not class II major histocompatibility complex molecules.
    Calin-Laurens V; Forquet F; Mottez E; Kanellopoulos J; Godeau F; Kourilsky P; Gerlier D; Rabourdin-Combe C
    Eur J Immunol; 1991 Mar; 21(3):761-9. PubMed ID: 2009914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of anti-CII TA M1-RNA on IFN-gamma induced major histocompatibility complex class II antigens expression on cultured human chondrocytes.
    He F; Guo R; Du X; Lu ZS; Weng JY; Lin W
    Transpl Immunol; 2007 Jun; 17(4):231-6. PubMed ID: 17493524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
    Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
    J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.
    SenGupta D; Norris PJ; Suscovich TJ; Hassan-Zahraee M; Moffett HF; Trocha A; Draenert R; Goulder PJ; Binder RJ; Levey DL; Walker BD; Srivastava PK; Brander C
    J Immunol; 2004 Aug; 173(3):1987-93. PubMed ID: 15265933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule.
    McGuire TC; Leib SR; Mealey RH; Fraser DG; Prieur DJ
    J Immunol; 2003 Aug; 171(4):1984-93. PubMed ID: 12902502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.